The latest price target for Evofem Biosciences (OTCQB:EVFM) was reported by Laidlaw & Co. on December 13, 2023. The analyst firm set a price target for $0.00 expecting EVFM to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Evofem Biosciences (OTCQB:EVFM) was provided by Laidlaw & Co., and Evofem Biosciences downgraded their hold rating.

There is no last upgrade for Evofem Biosciences

The last downgrade for Evofem Biosciences Inc happened on December 13, 2023 when Laidlaw & Co. changed their price target from N/A to N/A for Evofem Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evofem Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evofem Biosciences was filed on December 13, 2023 so you should expect the next rating to be made available sometime around December 13, 2024.

While ratings are subjective and will change, the latest Evofem Biosciences (EVFM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Evofem Biosciences (EVFM) is trading at is $0.01, which is out of the analyst’s predicted range.